Loading
A phase 2 trial of Active Comparator in advanced solid tumours, run by MetaFines, now recruiting.
Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 is a phase 2 interventional study registered as NCT07168226 by MetaFines, with 135 participants planned, started 2026-05-08 and due to reach its primary completion in 2028-04-30. Interventions recorded: Active Comparator, ASCA101 24.32mg/kg, ASCA101 32.43mg/kg and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/